Biopharmaceutic planning in pediatric drug development

Area of Science:

• Pharmaceutical Sciences
• Pediatric Pharmacology
• Biopharmaceutics

Background:

• Pediatric drug development is mandatory for all new drug programs.
• Age-appropriate formulations (e.g., suspensions, chewable tablets) are crucial for pediatric studies.
• Enabling formulations may be used in pivotal studies, followed by bioavailability/bioequivalence assessments.

Purpose of the Study:

• To highlight the importance of age-appropriate formulations in pediatric drug development.
• To emphasize the biopharmaceutical considerations in pediatric formulation development.
• To underscore the role of strategic biopharmaceutic data collection.

Main Methods:

• Review of standard practices in pediatric drug formulation.
• Analysis of biopharmaceutical strategies in clinical development.
• Emphasis on risk assessment and study planning.

Main Results:

• Development of age-appropriate formulations presents unique biopharmaceutical challenges.
• Bridging studies are often necessary when enabling formulations are used.
• Proactive biopharmaceutical data collection is key.

Conclusions:

• Strategic planning of biopharmaceutic data collection is essential for pediatric drug development.
• This planning significantly aids in risk assessment and study design.
• Successful development of pediatric formulations relies on thorough biopharmaceutical evaluation.